Key facts
- Ollin’s last known valuation is $144.0M (Sep 2025).
- It has raised $100.0M; the latest was Early Stage VC ($100.0M) in Sep 2025.
- Notable investors include ARCH Venture Partners, Mubadala Capital, Monograph Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Ollin
- ·The full record, as it builds
Funding rounds
No funding rounds for Ollin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ollin
Developer of biopharmaceutical therapies intended for vision-threatening ophthalmic diseases. The company offers therapies for conditions like wet age-related macular degeneration, diabetic macular edema, and thyroid eye disease, enabling patients to improve their vision and quality of life, by treating as well as preventing vision-related disease.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2022
- Employees
- 14
- Website
- ollin.bio/
- Ownership
- Privately Held (backing)
Ollin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ollin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ollin in its N-PORT filings yet. We sweep new filings monthly.